Human umbilical cord mesenchymal stem cells in irritable bowel syndrome: Mechanistic and translational insights

Abstract

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a prevalent functional gastrointestinal disorder characterized by chronic abdominal pain and loose stools, increasingly recognized as a condition driven by low-grade inflammation, epithelial barrier dysfunction, and disturbances of the gut microbiota rather than purely disordered motility. In the recent issue of World Journal of Stem Cells, Zhang et al report that human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) ameliorate IBS-D - like disease in rats by attenuating mucosal inflammation, restoring tight junction protein expression, and stabilizing the intestinal microbiome. This editorial critically appraises their work from a translational perspective, highlighting the novelty of targeting the gut-immune-microbiome axis with hUC-MSCs in a functional bowel disorder. We discuss potential mechanisms of action, including paracrine immunomodulation, epithelial repair, and microbiome-short chain fatty acid-immune cross-talk, and relate these to current concepts of IBS-D pathophysiology. Key limitations of the animal data, gaps in human evidence, and challenges for clinical translation - such as patient selection, optimal dosing and delivery, and regulatory demands for advanced therapy medicinal products - are addressed. Finally, we propose priorities for early-phase clinical trials that integrate mechanistic biomarkers with patient-centered outcomes to determine whether hUC-MSCs can transition from experimental therapy to a realistic, disease-modifying option for IBS-D.

Key Words: Irritable bowel syndrome; Mesenchymal stem cells; Umbilical cord; Intestinal mucosa; Diarrhea; Microbiota; Translational medical research; Cell- and tissue-based research

Core Tip: Diarrhea-predominant irritable bowel syndrome is increasingly linked to immune activation, intestinal barrier dysfunction, and gut microbiota imbalance rather than isolated motility disturbances. In a recent rat model, human umbilical cord mesenchymal stem cells reduced inflammatory cytokines, restored tight junction protein expression, and stabilized microbial diversity. This editorial situates these findings within current concepts of diarrhea-predominant irritable bowel syndrome pathophysiology, explores how human umbilical cord mesenchymal stem cells might function as a multi-target biological therapy, and outlines key limitations, regulatory hurdles, and priorities for early-phase clinical trials needed to translate this strategy into patient care.

This editorial refers to “Human umbilical cord mesenchymal stem cells alleviated diarrhea-type irritable bowel syndrome by improving intestinal function” by Zhang et al, 2025; https://doi.org/10.4252/wjsc.v17.i12.112100.

---

INTRODUCTION

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a functional gastrointestinal disorder marked by chronic, relapsing abdominal pain with frequent loose stools. It is highly prevalent, affecting approximately 5%-15% of the global population, and significantly impairs quality of life[1,2]. Unlike inflammatory bowel diseases (IBD), IBS lacks gross structural pathology, yet its pathogenesis is multifactorial. Emerging evidence implicates subtle immune activation, intestinal barrier dysfunction, and disturbances in the gut microbiota in IBS[3-8]. In IBS-D, downregulated tight junction proteins impair epithelial integrity, and patients often exhibit coinciding phenotypes of chronic low-grade inflammation and visceral hypersensitivity[5,8,9]. Concurrently, dysbiosis of the gut microbiome is common, with distinct microbial signatures observed in IBS subtypes[4,6,10]. Standard therapies for IBS-D include a symptom-amelioration-focused strategy: Dietary modification, antibiotics like rifaximin, motility agents, and neuromodulators. There is a clear need for innovative treatments targeting the underlying pathophysiology - namely, modulating the immune response, healing the gut barrier, and rebalancing the microbiota.

Among emerging biologic options, mesenchymal stem cells (MSCs) offer a unique combination of immunomodulatory, barrier-restorative, and microbiota-modifying properties that distinguish them from single-target cytokine antagonists or small-molecule agents[11-13]. Human umbilical cord-derived MSCs (hUC-MSCs) are particularly attractive because they are highly proliferative, relatively immunologically naïve, and scalable[11,14,15]. Clinical and preclinical data in inflammatory and autoimmune diseases further suggest that MSCs can integrate immune regulation, epithelial restitution, and stromal/tissue regeneration within a single product, aligning closely with the multifactorial pathophysiology of IBS-D[13,14,16].

Zhang et al[17] recently published a study in World Journal of Stem Cells investigate a regenerative medicine approach to IBS-D by using hUC-MSCs to address the disease at its biological roots. Here, we provide a commentary on the novelty and significance of their findings, highlighting the potential of hUC-MSC therapy for treating IBS-D. We discuss how hUC-MSCs could offer therapeutic benefits by reducing gut inflammation, restoring epithelial barrier function, and balancing the gut microbiome, while also considering the challenges of translating this medical strategy into clinical practice.

TRI-MODAL THERAPEUTIC EFFECTS

Zhang et al[17] used a well-established IBS-D rat model that combines intracolonic acid insult with psychological stress to evaluate hUC-MSC therapy[18,19]. The authors administered a single intravenous dose of fluorescent-labeled hUC-MSCs at low, medium, or high cell numbers to different groups, then compared outcomes with untreated IBS-D model rats[17]. hUC-MSC treatment improved three main pathological aspects of IBS-D. First, treated rats showed reduced colonic inflammation, with pro-inflammatory cytokine levels significantly lower than in untreated IBS-D animals[17]. Second, hUC-MSCs enhanced epithelial barrier function, as evidenced by increased expression of tight junctions and other barrier-related proteins in colonic tissue[17]. Third, hUC-MSC therapy helped normalize the gut microbiota, with the treated rats maintaining greater microbial diversity and a more balanced flora despite the IBS-inducing insults[17]. These biological improvements resulted in measurable phenotypic differences, whereby hUC-MSC-treated rats experienced less weight loss and stool form and water content closer to those of healthy controls[17].

Notably, Zhang et al[17] confirmed that the administered hUC-MSCs engrafted in the damaged colon tissue. By day 14 post-treatment, fluorescently labeled MSCs were detectable in the colonic mucosa, indicating activity at the injury sites[17]. This colonization aligns with previous findings that systemically administered MSCs can migrate to inflamed regions of the gut[11,14,20,21]. It likely underpins the localized effects on the mucosal immune environment, barrier repair, and microbial habitat. The multi-dose design further showed a dose-response trend for certain outcomes[17]. While even the lowest dose provided some benefit, higher hUC-MSC doses tended to yield greater improvements in specific parameters (i.e., a trend toward reduced visceral hypersensitivity at the highest dose)[22]. Interestingly, despite strong anti-inflammatory and barrier-enhancing effects, the intervention only modestly impacted visceral pain sensitivity in this model[17,22]. Overall, the collective findings from Zhang et al’s preclinical study[17] highlight the distinctive multifaceted mode of action of hUC-MSCs, which could be particularly beneficial in a complex syndrome such as IBS-D.

Important advancements in IBD

Recent advances in IBD therapeutics provide a valuable roadmap for future successes in IBS, particularly regarding MSC-based and MSC-derived exosome strategies. In preclinical colitis models, combining hUC-MSCs and their exosomes with standard IBD pharmacotherapy has been shown to synergistically modulate T-cell responses, rebalance cytokine profiles, and attenuate mucosal damage[23]. HUC-MSC-derived exosomes also repair IBD by activating the SIRT1-FXR pathway in macrophages, highlighting how precise targeting of innate immune metabolism can drive durable mucosal healing and suggesting analogous opportunities to reprogram macrophage function in low-grade inflammatory IBS[24]. Beyond immune cells, exosomes from hUC-MSCs regulate lymphangiogenesis via the miR-302d-3p/VEGFR3/AKT axis to ameliorate IBD, illustrating that vascular and lymphatic remodeling is an actionable component of the intestinal repair microenvironment[25]. Early-phase clinical data in luminal ulcerative colitis now demonstrate that expanded hUC-MSCs are safe and potentially efficacious in humans, thereby providing a regulatory and logistical template for future IBS trials[26]. Coordinating immune regulation, epithelial restitution, and stromal/tissue regeneration are principles that align closely with emerging views of IBS as a disorder of barrier integrity, immune-neural crosstalk, and dysregulated repair, which can be leveraged to design next-generation biological therapies for IBS, informed directly by IBD experiences[13].

MECHANISTIC INSIGHTS: IMMUNOMODULATION, BARRIER RESTORATION, AND MICROBIOME REBALANCING

Immune modulation and anti-inflammatory effects

MSCs are well-known for their potent immunomodulatory properties[11,12,27]. Zhang et al[17] found that treated IBS-D rats had lower levels of key inflammatory mediators in the colon, such as tumor necrosis factor-α (TNF-α) and interleukins (ILs), indicating reduced mucosal inflammation. These findings support existing research showing that MSCs can suppress harmful immune responses in the gut. MSCs release various anti-inflammatory factors - including TNF-α-stimulated gene 6, prostaglandin E2, indoleamine 2,3-dioxygenase, and transforming growth factor-β - that act on immune cells to decrease inflammation[12,14,21,27,28]. Through paracrine signaling, MSCs promote the development of regulatory T cells and M2-like anti-inflammatory macrophages while inhibiting pro-inflammatory T cells and M1 macrophages[12,29,30]. Both animal models and clinical studies of IBD show that MSC treatment reduces TNF-α and IL-6 levels and concurrently increases the anti-inflammatory cytokine IL-10, thereby shifting the immune response toward resolution of inflammation[11,14,20,28]. Animal models even suggest synergism between traditional anti-inflammatory agents and hUC-MSCs[23]. Therefore, the decreased cytokine levels seen in hUC-MSC-treated IBS-D rats likely result from MSC-driven immune reprogramming[11,12,14,28]. This immune modulation has important clinical significance. Although IBS-D is not a typical inflammatory disease, many patients exhibit low-grade mucosal immune activation, such as increased intestinal mast cells and activated T cells[5-8]. By restoring normal mucosal immune function, MSC therapy could improve IBS-D symptoms exacerbated by immune-mediated mechanisms, including post-infectious IBS with ongoing inflammation[5-8].

Restoration of epithelial barrier function

A key aspect of Zhang et al’s work[17] is demonstrating that hUC-MSCs aid in repairing the gut’s barrier in IBS-D. Rats treated with MSCs showed increased expression of tight junction proteins, which regulate paracellular permeability[17]. This aligns with reports that MSCs promote epithelial healing in the gastrointestinal tract[14,21,27]. MSC-derived factors, such as prostaglandin E2 and TNF-α-stimulated gene 6, can improve epithelial junction assembly and reduce leakiness[14,21,28]. In experimental colitis models, MSC secretions have been shown to upregulate tight junction molecules (i.e., claudins, occludin, and zonula occludens-1) and to support the survival and proliferation of intestinal epithelial cells[14,28]. By secreting factors that accelerate mucosal repair and by directly differentiating or fusing into local epithelial-like cells - a key feature suggested by some studies - MSCs help rebuild the gut barrier[11,14,20,21]. This is critically important because IBS-D patients often have increased epithelial permeability, in which barrier defects allow luminal irritants to penetrate and trigger neuronal and immune responses, leading to diarrhea and pain[5,8,9]. Strengthening the epithelial barrier can prevent this process, reducing abnormal sensory signaling and fluid secretion[5,8,9]. Notably, a recent study in IBS-D patients linked downregulation of the tight junction protein claudin-1 to a leak flux-type diarrhea[9]. Restoring junctional integrity with hUC-MSC therapy addresses a root cause of IBS-D’s characteristic loose stools[5,9]. This barrier-protective effect of MSCs also supports their immunomodulatory role. A less permeable gut lining results in less continuous immune stimulation from luminal contents, promoting long-term quiescence of inflammation[5,8,21,27].

Microbiome rebalancing

Perhaps the most novel insight from Zhang et al[17] is the ability of hUC-MSCs to influence the gut microbiome composition in IBS-D. The treated rats maintained a richer and more diverse gut microbial population than untreated IBS-D rats[17]. Dysbiosis is strongly linked to IBS; for example, patients with IBS-D often exhibit lower microbial diversity and altered taxonomic distributions compared with healthy individuals[4,10,28]. One likely mechanism by which hUC-MSCs may normalize the gut microbiota is by reducing intestinal inflammation and improving the intestinal barrier and mucus layer. MSCs create a more favorable environment for commensal bacteria to flourish[15,16,21,27,28]. Supporting this, research in colitis models has shown that hUC-MSC treatment increases the abundance of beneficial short chain fatty acid (SCFA)-producing bacteria, such as Akkermansia and Faecalibaculum, in the gut[15,16]. Liu et al[15] demonstrated that hUC-MSCs alleviated experimental colitis partially by remodeling the gut microbiota and increasing luminal SCFA levels. These higher SCFA concentrations, in turn, were linked to the expansion of regulatory T cells and the suppression of pro-inflammatory Th17 cells, revealing a microbiome–immune healing axis[15]. It is plausible that in Zhang et al’s IBS-D model[17], a similar process occurred: MSC-driven microbial shifts (i.e., an increase in SCFA producers or a reduction of pathobionts) could help restore immune balance and influence the neuromotor function of the gut[4,6,7,15,16]. Additionally, MSCs may secrete antimicrobial peptides or metabolites that directly modulate microbiota composition. This is an area requiring further inquiry. It suggests that hUC-MSC therapy might offer a dual benefit in IBS-D: Not only correcting host dysfunctions but also promoting a eubiotic microbiome, which could provide resilience against IBS symptom flares[4,6,7,10,15,16]. Since microbiome-targeted therapies like antibiotics, probiotics, and diet are already part of IBS treatment, MSCs’ ability to modulate the microbiome makes them particularly appealing as a comprehensive therapeutic option that targets an underlying cause of illness[4,6,7,10,15,28]. To better illustrate how hUC-MSCs address the multifaceted pathology of IBS-D, Table 1 summarizes the key therapeutic effects observed (or anticipated) with hUC-MSC therapy, the underlying mechanisms of action, and the translational considerations for each.

Table 1 Therapeutic effects of human umbilical cord mesenchymal stem cells in diarrhea-predominant irritable bowel syndrome, showcasing mechanisms, translational capabilities, and challenges to human-based treatment.

Therapeutic effect of hUC-MSCs	Mechanism of action	Translational considerations
Reduction of mucosal inflammation	Secretion of anti-inflammatory factors (i.e., TSG-6, PGE2, IDO, and TGF-β) and cytokines (IL-10); induction of regulatory T cells and M2 macrophages; suppression of TNF-α, IL-6, and pro-inflammatory immune cells	Benefits: Addresses low-grade inflammation underlying IBS-D; may provide durable relief by resolving immune triggers. Challenge: IBS immune activation is subtle, therefore selecting specific patients with inflammatory phenotypes may be necessary. Regulatory approval will require clear clinical benefit given safety risks of systemic cell therapy. Although, it should be noted that MSCs have a substantiated record of safety
Restoration of intestinal barrier	Paracrine release of growth factors (i.e., EGF and KGF) and PGE2 that promote epithelial repair; upregulation of tight junction proteins and mucins; differentiation into epithelial-like cells or stimulation of resident stem cells	Benefits: Reduces gut permeability, which can alleviate diarrhea and pain by preventing luminal irritants from triggering enteric nerves and immune responses. Challenge: Delivering MSCs to mucosal sites in patients is difficult; intravenous cells may consolidate in the lungs or spleen. Optimizing delivery (i.e., via endoscopy or multiple doses) and demonstrating barrier function in humans, without a list of straightforward biomarkers, are concerns
Rebalancing of gut microbiota	Indirect modulation via improved intestinal environment (i.e., less inflammation, better barrier, and more nutrients for commensals); possible secretion of antimicrobial peptides or metabolites that favor growth of beneficial bacteria (i.e., SCFA producers)	Benefit: A eubiotic microbiome can have systemic benefit, increasing SCFAs that enforce immune tolerance and fortify the gut barrier. Restoring microbial diversity may yield sustained symptom improvement beyond the treatment period. Challenge: Human microbiome responses may vary, since personalized factors influence outcomes. Regulatory agencies will expect mechanistic clarity, and attributing clinical improvement to microbiota changes is complex. Combining MSC therapy with microbiome-based interventions (pre/postbiotics or diet) might be explored to enhance synergistic effects
Alleviation of IBS symptoms (i.e., diarrhea and pain)	Multi-modal actions above converge to reduce core IBS-D symptoms: Less inflammatory signaling and conservative epithelium mitigate urgency/diarrhea; normalized microbiota and immune profile may reduce gas and bloating; MSC secretions (i.e., NGF and opioid-like peptides) could modulate enteric neurons to dull pain perception.	Benefits: Direct improvement in patient-reported outcomes (i.e., stool frequency/consistency and abdominal pain) would fulfill the primary goal of therapy and improve quality of life. MSC therapy could reduce reliance on multiple symptom-directed drugs by addressing upstream causes. Challenge: Pain in IBS has a central nervous system component; MSCs might not fully address brain-gut dysregulation. Placebo response rates in IBS trials are high, necessitating rigorous trial designs to prove efficacy. Long-term safety must be confirmed, especially if repeat infusions are required for chronic management

hUC-MSCs: Human umbilical cord-derived mesenchymal stem cells; TSG-6: Tumor necrosis factor-α-stimulated gene 6; PGE2: Prostaglandin E2; IDO: Indoleamine 2,3-dioxygenase; TGF-β: Transforming growth factor β; IL: Interleukin; TNF-α: Tumor necrosis factor-α; IBS-D: Diarrhea-predominant irritable bowel syndrome; IBS: Irritable bowel syndrome; MSCs: Mesenchymal stem cells; EGF: Epidermal growth factor; KGF: Keratinocyte growth factor; SCFA: Short chain fatty acid.

INNOVATION, LIMITATIONS, AND FUTURE DIRECTIONS

Zhang et al’s work[17] represents one of the first demonstrations that cell therapy can improve IBS-like diseases in preclinical models by targeting the gut-immune-microbiome axis[18,19,22]. The comprehensive effectiveness of hUC-MSCs - simultaneously addressing inflammation, the barrier, and the microbiota - represents a breakthrough concept for IBS-D, where multi-system dysregulation has long been acknowledged but rarely addressed in an integrated way[5-9]. The study also presents practical innovations, such as using three different cell doses to suggest an optimal therapeutic range and confirming MSC engraftment in gut tissue, which supports the mechanistic insights[17]. Additionally, by utilizing hUC-MSCs (which are allogeneic and easily scalable from discarded umbilical cords), the authors emphasize a cell source with real-world potential for clinical application[11,14,15,17]. hUC-MSCs are highly proliferative and immunologically naive cells that, in some studies, demonstrate greater immunomodulatory effects than adult tissue-derived MSCs[11,12]. These qualities make them strong candidates for future cell therapy products[11,12,14]. At a conceptual level, much of the benefit of exogenous MSCs may derive from their ability to condition the immune milieu and activate resident epithelial, stromal, and stem/progenitor cells[13,20,21]. Future strategies could include not only direct infusion of hUC-MSCs, but also exosome-based and paracrine-mimetic approaches that more selectively harness and amplify the patient’s own regenerative capacity while minimizing long-term cell-related risks[23,25].

However, it is important to recognize the study’s limitations. First, the therapy was tested in a rat IBS-D model, which, although well-characterized, cannot fully replicate the complexity of human IBS[17-19]. The model induces IBS-D through chemical injury and stress, focusing on peripheral mechanisms; it may not reflect central pain processing or the psychosocial triggers that influence IBS in patients[7,18,19]. It is also important to note that the induction of chemical injury and stress used by Zhang et al[17] may overrepresent the contribution of these mechanisms relative to the heterogeneous drivers of IBS-D in humans. Given that IBS-D in clinical cohorts arises from a broad spectrum of interacting factors that vary substantially among patients, a model that is heavily weighted toward mucosal injury and stress-induced hypersensitivity may overestimate the extent to which immune and barrier repair alone can normalize symptoms in real-world IBS-D populations[5,7,8]. In fact, Zhang et al[17] noted minimal improvement in visceral hypersensitivity in treated rats, highlighting that neural components of IBS might require additional or alternative interventions[5,7,20,22]. This is a critical sign for clinical translation, because pain and urgency - not biomarker normalization - drive most IBS-D health burden and treatment seeking[1,2]. Human data consistently indicate that central processing within the brain-gut axis, psychological stressors, and neuroimmune crosstalk contribute substantially to IBS-related pain, often disassociated from the degree of peripheral inflammation or barrier dysfunction[5,7]. The disconnect between robust improvements in mucosal biology and only limited changes in visceral pain in this model, therefore, cautions against assuming that correcting immune and barrier abnormalities will automatically translate into meaningful symptom relief. Future MSC-based trials in IBS-D will need to prioritize validated pain and global symptom endpoints and may ultimately require combination strategies that pair peripherally acting cell therapies with neuromodulatory or psychobiological interventions[5,7,22]. Second, the sample size was small (n = 12 per group, with subgroup analyses at multiple time points), which the authors admit may have limited the statistical power to detect changes in some outcomes[17]. This might explain why only high-dose hUC-MSCs showed trends toward pain relief; a larger sample could reveal significant benefits in sensory measures. Although Zhang et al[17] observed apparent dose-response trends, particularly for visceral hypersensitivity at the highest hUC-MSC dose, the small group size limits statistical power and increases susceptibility to both type I and II errors. These dose-related patterns should therefore be interpreted as hypothesis-generating rather than definitive, and future preclinical work will need larger cohorts and prespecified dose-ranging designs to reliably delineate the therapeutic window for hUC-MSCs. Third, and most importantly, no human data were provided. As the authors mention, there is currently no clinical verification data[17]. The transition from rodent models to human IBS-D trials is complex, given the differences in immune system intricacy, microbiome diversity, and symptom assessment between rats and humans[2,3,5-7,28]. Safety is another crucial aspect - although MSCs have an excellent safety profile in numerous trials for other conditions, their application in a non-life-threatening disorder such as IBS will inevitably require stringent risk-benefit evaluation[6,11,12,14,16]. Fortunately, no major safety concerns, such as malignancy or organ fibrosis, have emerged after clinical use of MSCs in thousands of patients with various diseases[6,11,12,14]. This suggests promising potential for translating hUC-MSCs into IBS-D treatment, provided that efficacy is demonstrated; however, the long-term safety profile in humans cannot currently be delineated.

Looking ahead, several key steps must be taken to translate Zhang et al’s promising findings[17] into clinical practice. Larger animal studies or ex vivo human intestine models could help refine the understanding of optimal dosing, timing, and delivery routes[18,19]. It will also be crucial to identify biomarkers in IBS-D patients that predict responsiveness to MSC therapy. Early-phase clinical trials (phase I/II) involving carefully selected IBS-D patients could focus on safety and preliminary efficacy, possibly using allogeneic hUC-MSCs from a certified cell bank[11,12,14,15]. The design of IBS trials needs to consider the high placebo effect, so controlled, possibly cross-over designs, and the use of objective biomarkers - such as gut permeability tests, mucosal cytokine levels, and microbiome analyses - alongside symptom scores will make efficacy claims more reliable[1,2,6,7]. To more concretely address the high placebo response characteristics of IBS trials, early-phase hUC-MSC studies should combine enrichment and stratification strategies with rigorous endpoint selection. Enrichment could focus on IBS-D patients with objective evidence of barrier dysfunction or low-grade inflammation - such as increased intestinal permeability, claudin-1 downregulation, or subtle inflammatory signatures - who are more likely to benefit from a mucosal repair-oriented intervention[5,8,9]. Stratifying participants by post-infectious status, barrier phenotype, or microbiota profile would enable exploratory subgroup analyses and reduce biological noise[4,7,10]. Finally, trials should composite primary outcomes that integrate abdominal pain, stool form/frequency, and patient global relief, alongside secondary mechanistic readouts such as permeability assays, mucosal cytokines, and microbiome sequencing to anchor symptomatic changes in objective, measurable biology[1,5,8].

It remains uncertain whether hUC-MSC therapy will induce durable remission in IBS-D or primarily provide transient modulation of an inherently dynamic gut-immune-microbiota axis. Mechanistically, MSCs are best viewed as niche modulators that remodel the intestinal immune microenvironment and support epithelial and stromal repair rather than as a permanent replacement for the host’s own stem and immune cell compartments[12,13]. In preclinical IBD models and early clinical studies, MSCs appear to promote a shift toward regulatory immune phenotypes and to enhance endogenous regenerative responses, suggesting that they may help reset dysregulated immunity but are unlikely to abolish all future disease susceptibility[11,14,16]. Ultimately, the question of whether exogenous MSCs can induce lasting immune tolerance and stabilize host stem cell function in IBS-D will require longitudinal models and human trials with extended follow-up.

Fortunately, umbilical cord MSCs can be expanded to produce large, cryopreservable cell batches, and previous human studies in other fields (i.e., using hUC-MSCs for graft vs host disease or degenerative diseases) offer a model for scaling this therapy[11,12,14,15]. Collaboration among stem cell researchers, gastroenterologists, and microbiome experts will be essential for designing trials that can demonstrate how hUC-MSCs benefit those with IBS-D, such as by monitoring changes in patients’ mucosal immune cell profiles, junctional protein expression, and microbiota composition before and after treatment[6,7,10,15,16]. Such correlative studies could confirm in humans the mechanistic triad observed by Zhang et al[17] in rats and potentially identify surrogate endpoints for future larger trials[6,7,10,15,28].

CONCLUSION

Zhang et al[17] have opened an exciting new path for IBS-D therapy by demonstrating that hUC-MSCs can significantly reduce disease features in a preclinical model. Their work highlights a successful blend of basic stem cell research with gastroenterology, providing insights that foster optimism for clinical application[2,5-7,9,12,14]. The innovation lies not only in what hUC-MSCs achieved - such as reducing inflammation, strengthening the gut barrier, and rebalancing the microbiota - but also in the concept that a single therapeutic agent can address multiple interconnected pathological areas[2,5-7,9,12,15,27]. For clinicians and researchers in the IBS field, these findings prompt a rethinking of treatment strategies: Rather than managing IBS-D with a fragmented, symptom-by-symptom approach, regenerative cell therapy could be used to target core dysfunctions and promote long-term remission. In summary, hUC-MSC therapy is a paradigm-shifting candidate for IBS-D treatment[17]. By harnessing the cells’ natural ability to regulate immune balance, promote tissue repair, and maintain microbial homeostasis, we move closer to a future in which IBS-D may not only be managed but also cured through biological therapy[2,5,6,12,15].